The only efficacy data are the supplier's: 17 women, 28 days, a cream with 10% of the SNAP-8 solution, and a maximum wrinkle-depth reduction of 63% around the eyes, with no control group, no mean reported on the sheet, and no peer-reviewed publication. The two peer-reviewed human studies of the peptide are of microneedle patches containing several other actives, from the patches' manufacturers, and cannot attribute anything to SNAP-8. Argireline, its shorter parent, has one randomized placebo-controlled trial; SNAP-8 has none.

Is SNAP-8 stronger than Argireline?

The supplier says so, and the supplier ran the comparison. Lipotec's material describes SNAP-8 as an elongation of Argireline with greater activity in its own cell assays and topography tests; secondary sources repeat figures of roughly 35% versus 27% wrinkle reduction at equivalent concentrations. We could not find that comparison in a journal. The mechanism claim is the same for both peptides, and the FDA penetration study of the shorter peptide found 0.01% of a 10% dose reaching the epidermis; nothing suggests the longer peptide penetrates better.

What percentage of SNAP-8 is in a 10% SNAP-8 product?

About 0.005% peptide. The raw material Lipotec sells is a solution containing 0.05% acetyl octapeptide-3, and the recommended use is 3 to 10% of that solution in a finished product. Ten percent of a 0.05% solution is 0.005%, or 50 parts per million; three percent is 0.0015%. A label reading SNAP-8 10% is describing the amount of supplier solution, not the amount of peptide, and that is also the concentration the supplier's 17-woman test used.

There is no published safety assessment of acetyl octapeptide-3 that we could find; the Cosmetic Ingredient Review has assessed its parent, acetyl hexapeptide-8, as safe up to 0.005% with data insufficient above that. At the supplier's recommended dose, a SNAP-8 product delivers about 0.005% peptide, inside that ceiling by coincidence of arithmetic. The two microneedle-patch studies reported no adverse effects in 24 and an unstated number of subjects. That is the whole record.

Which products contain SNAP-8?

It appears in eye creams and serums from brands including HydroPeptide, iS Clinical, Le Mieux, Colleen Rothschild, Image Skincare and Freezeframe, per the INCIDecoder listing, and in DIY booster solutions sold at 3 to 10%. Almost none state a peptide percentage; those that say 10% mean 10% of the supplier solution. We do not rank products and no product on this list has been through our review standard.

How long does SNAP-8 take to work?

The supplier's test measured at 28 days and reports a maximum, not a typical, result. The patch studies measured at 28 days and 12 weeks. Nothing longer exists, and nothing exists for a serum at all.

SNAP-8 (Acetyl Octapeptide-3): The Supplier's Study, the 0.05% Solution, and What 10% Really Means

The only efficacy study of SNAP-8 is the supplier's own, on 17 women; the raw material is a 0.05% solution; and a product labelled 10% SNAP-8 contains about 0.005% peptide. The evidence as it stands, and the arithmetic the label leaves out.

SNAP-8 is sold as "Argireline, but stronger", and the claim comes from one place: the company that makes both. This page reads the supplier's product sheet, does the arithmetic the label skips, searches the literature for anything independent, and reports what is there. The short version is that the evidence for SNAP-8 is a 17-woman test on a manufacturer's datasheet, and that a "10% SNAP-8" product contains about 0.005% peptide.

What it is

Acetyl octapeptide-3 is an eight-amino-acid peptide, Argireline's six-residue sequence with two more residues added. Lipotec, the Barcelona company that developed Argireline and is now part of Lubrizol, describes it on its sheet as an "octapeptide that is an elongation of the hexapeptide argireline®", "a new analogue of the N-terminal end of SNAP-25, that competes with the native protein for a position in the SNARE complex, essential for the muscle contraction" (Lipotec SNAP-8 product sheet). The mechanism claim is identical to Argireline's, and the same objection applies: the FDA study of the shorter peptide found that 0.22% of a 10% dose stayed in the stratum corneum of human skin and 0.01% reached the epidermis after 24 hours, which is far from a nerve ending. Our Argireline page covers that study; nothing published suggests the longer peptide penetrates better.

The supplier's evidence

The sheet gives three in-vitro assays (SNARE-complex formation, catecholamine release in chromaffin cells, glutamate release in neurons) and one in-vivo test, quoted in full: "Skin topography analysis were performed to measure the effectiveness of a cream containing 10% snap-8 Solution, applied twice a day. Silicon imprints were obtained from around the eyes of 17 women volunteers pre-test and after the 28 day treatment. Analyses of the imprints were performed by confocal profilometry." Result: "The maximum reduction value of wrinkle depth was 63%." A maximum is the best single result among 17; the sheet gives no mean, no spread, no vehicle control and no publication. The document's own footer says its data "are presented free and for guidance only" and that the recipient must "not present this publication as evidence of finished product claim substantiation to any regulatory authority." Retail pages round this to "63% wrinkle reduction" and drop the rest.

Secondary sources cite a head-to-head in which SNAP-8 reduced wrinkles by about 35% against 27% for Argireline at equal concentrations; we found no journal publication of it and report it as supplier material.

The arithmetic

The sheet's "Appearance" line: "Transparent solution containing 0.05% active ingredient." Its dosage line: "3–10%". So the raw material is a 0.05% peptide solution, and a finished product contains 3 to 10% of that solution.

Label	Supplier solution in product	Acetyl octapeptide-3 in product
"SNAP-8 3%"	3%	0.0015% (15 ppm)
"SNAP-8 10%"	10%	0.005% (50 ppm)
The supplier's 17-woman test	10%	0.005%

This is not a criticism of the products; it is what the number means. It has one consequence worth noticing: 0.005% is, to the digit, the concentration the Cosmetic Ingredient Review panel set as the assessed ceiling for the parent peptide, acetyl hexapeptide-8. A "10% Argireline" serum is 2,000 times above that ceiling; a "10% SNAP-8" serum is at it, because the SNAP-8 percentage counts the solution and the Argireline percentage counts the peptide.

What the literature holds

We searched PubMed on 2026-09-05 for acetyl octapeptide-3 and SNAP-8. Two human studies exist, both of dissolving microneedle patches carrying several actives, both from the patch's maker:

A split-face comparison in 24 healthy subjects of an overnight hyaluronic-acid microneedle patch containing acetyl octapeptide-3, ascorbic acid 2-glucoside and cyclic lysophosphatidic acid, against a plain hyaluronic-acid patch, over 28 days; the loaded patch improved eye wrinkles, water loss, elasticity and lifting with no adverse effects. Affiliation: Raphas Co., Seoul, the patch's manufacturer (Shin et al., Annals of Dermatology 2024).
A 12-week open-label study of a microneedle patch containing arginine/lysine polypeptide, acetyl octapeptide-3, palmitoyl tripeptide-5, adenosine and seaweed extracts, reporting a 25.8% decrease in fine lines and wrinkles. Affiliation: Imperial Bioscience, Brighton, the product's maker (Avcil et al., Journal of Cosmetic Dermatology 2020).

Neither can attribute anything to SNAP-8, and neither is a serum. There is no peer-reviewed trial of acetyl octapeptide-3 in a cream or serum, controlled or otherwise, indexed on PubMed. The 2025 review of acetyl hexapeptide-8 that we used for the Argireline page does not treat SNAP-8 separately. We searched the Cosmetic Ingredient Review's reports database for acetyl octapeptide-3 and found no assessment.

Products

INCIDecoder lists acetyl octapeptide-3 in products from HydroPeptide (Power Serum), iS Clinical (Youth Eye Cream), Le Mieux (Eye Wrinkle Corrector), Colleen Rothschild (Age Renewal Super Serum), Image Skincare (MD Restoring Collagen Recovery Eye Gel), Freezeframe (Revital Eyes) and others, none stating a percentage (INCIDecoder). DIY suppliers sell the 0.05% solution itself for home formulation at 3 to 10%. We do not rank these products; none has been through our review standard, and the ingredient's evidence base would not support ranking them by SNAP-8 content in any case.

What the evidence does not show

It does not show, in any independent study, that SNAP-8 reduces wrinkles in a serum or cream; it does not show that it outperforms Argireline outside the supplier's own tests; it does not show that it reaches the muscle whose contraction it is meant to inhibit; and it does not carry a safety assessment. It does show one manufacturer's 28-day, 17-woman topography test with a best-case result of 63%, and two manufacturer patch studies in which the peptide was one of several actives.

Sources and dates

Opened 2026-09-05: the Lipotec SNAP-8 product sheet (COSSMA product-information archive, edition 10B); Shin et al. 2024 (PMID 39082657); Avcil et al. 2020 (PMID 31134751); INCIDecoder's ingredient page; the CIR reports database (no entry found); the FDA penetration study of acetyl hexapeptide-8 (Kraeling et al. 2015, PMID 24754410) via our Argireline page. Lubrizol's current SNAP-8 product page blocked our request and is not quoted. Corrections go to the contact page; our review standard is on the testing notes page.